COLL logo

COLL Collegium Pharmaceutical, Inc.

NASDAQ Global Select · Drug Manufacturers - Specialty & Generic · Healthcare

$24.72
-0.49 (-1.94%)

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse.…

Market Cap: $768.18Mwww.collegiumpharma.com

Price

No data yet.

Social Signal Score

48
5d
—
30d
48
4 mentions
—
60d
48
9 mentions
—
90d
50
11 mentions
—
news: 11

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 3Sell 1Strong Sell 0
Avg price target$45.4+83.7%
Low $35Median $48High $50
Current Consensus

Revenue

$216.34M+16503.15%
$1.30M$72.98M$144.66M$216.34M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$7.47
$7.41–$7.53
4 analysts
FY2026
$7.46-0% YoY
$7.28–$7.58
4 analysts
FY2027
$7.08-5% YoY
$5.39–$8.40
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Vikram Karnani
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
423
Beta
0.73
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
0.92
www.collegiumpharma.com